Sustained release injectable compositions containing deslorelin

A sustained-release injectable composition with deslorelin microparticles and biodegradable polymers addresses the pain and duration limitations of existing methods by regulating release rates and ensuring uniform particle size, providing effective testosterone suppression for extended periods.

JP7580139B2Active Publication Date: 2024-11-11INVENTAGE LAB INC +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023020774
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-02-18
Filing Date
2023-02-14
Publication Date
2024-11-11
Estimated Expiration
2043-02-14

AI Technical Summary

Technical Problem

Existing methods for chemical castration using deslorelin cause significant pain to animals and require immediate high doses to be effective, leading to initial over-release and receptor deformation, which limits the duration of testosterone suppression.

Method used

A sustained-release injectable composition containing deslorelin microparticles and biodegradable polymers, formulated to regulate release rates and maintain effective testosterone suppression for over a month without initial over-release, using specific ratios and manufacturing processes to ensure uniform particle size and distribution.

Benefits of technology

The composition achieves continuous testosterone suppression for up to 24 months by preventing initial over-release and ensuring uniform microparticle degradation, maintaining effective deslorelin levels for the desired duration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580139000014
    Figure 0007580139000014
  • Figure 0007580139000015
    Figure 0007580139000015
  • Figure 0007580139000016
    Figure 0007580139000016
Patent Text Reader

Abstract

To provide a sustained-release injectable composition containing uniform microparticles of deslorelin, where the release rate of deslorelin is controlled at a target site so that initial over-release is prevented and an amount sufficient for the effects of deslorelin to be exhibited is exposed, and thus the effect of the deslorelin can be exhibited for at least one month, and to provide a production method thereof.SOLUTION: Disclosed is a sustained-release injectable composition containing microparticles where the microparticles contain deslorelin and a biodegradable polymer, and the value of Cmax1d-28d / Cmax0-1d (Equation 1) is from 1 to 10, where Cmax1d-28d is the maximum blood concentration of deslorelin within 1 to 28 days after injecting the injection product, and Cmax0-1d is the maximum blood concentration of deslorelin within one day after injecting the injection product, when the composition for sustained-release injection comprising deslorelin is administered as an injection product to a beagle dog to measure the blood concentration of deslorelin.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a sustained release injectable composition comprising deslorelin, and more particularly to a sustained release injectable composition comprising microparticles in which deslorelin is uniformly distributed. [Background technology]

[0002] Orchiectomy (removal of the testicles) or castration of male ruminants is necessary for a variety of reasons, primarily to reduce aggression, reduce the risk of harm to humans and other animals, and make them easier to handle.

[0003] It may also be necessary during more dedicated breeding for weight gain, to avoid the risk of unwanted hybridization with genetically inferior potential males, or to provide better carcass quality by increasing the proportion of prime meat and fat deposits relative to the whole animal.

[0004] Castration methods include surgical procedures such as tracheotomy, vas ligation, torsion, testicular ligation, traction, partial castration, and bloodless castration, as well as methods that involve exposing the reproductive glands to a certain amount of sensitive radiation to render them incapacitated.

[0005] However, physical castration causes serious pain and stress to animals, and has been a problem in terms of animal welfare. European countries such as Switzerland, Norway, Belgium, and the Netherlands decided to ban physical castration of animals around 2009, and South Korea is also considering a similar measure (Thun R et al., Castration in male pigs: Techniques and animal welfare issues. Journal of Physiology and Pharmacology, 57, pp. 189-194, 2006).

[0006] Other suitable methods for sterilization and elimination of libido are chemical. In the 1960s, research began into the use of sclerosing substances injected directly into the testicles or spermatic cords with the goal of promoting total loss of testicular or spermatic cord function (sperm and androgenic hormone production).

[0007] Chemical sterilization has been attempted in monkeys, hamsters, rabbits, rats and dogs by intratesticular administration of several agents: ferrous chloride (Kar et al., 1965), danazol (Dixit et al., 1975), BCG (Das et al., 1982), zinc tannin (Fahim et al., 1982), glycerol (Weinbauer et al., 1985; Immegart 2000), glucose, NaCl (Heath et al., 1993), and tetracycline (Thompson et al., 2000). , 1987, Russell et al., 1987), DBCP (Shemi et al., 1988), lactic acid (Fordyce et al., 1989), zinc arginine (Fahim et al., 1993), sodium fluoride (Sprando et al., 1996), formalin (Balar et al., 2002), and calcium chloride (Samanta 1998, Jana et al., 2002), glacial potassium acetate permanganate (Giri et al., 2002). In ruminants, the intratesticular injection of lactic acid (Hill et al., 1985), tannic acid, zinc sulfate (Feher et al., 1985), alpha-hydroxypropionic acid (Cohen et al., 1995), formalin (Ijaz et al., 2000), and CastrateQuin14 (Soerensen et al., 2001) was used.

[0008] Recently, deslorelin, a synthetic analogue of GnRH (gonadotropin releasing hormone), has been utilized for chemical castration in male animals and for the treatment of benign prostatic hyperplasia in dogs.

[0009] However, the deslorelin is injected into the animal body as an implant, which causes considerable pain to the animal when it is administered.

[0010] For this reason, when using deslorelin as a chemical castration agent, it is necessary to develop a product that can maintain its effectiveness as a temporary sterilization agent for a long period of time without causing significant pain to the animal. [Prior art documents] [Patent documents]

[0011] [Patent Document 1] Korean Patent Publication No. 10-2012-0052355 Summary of the Invention [Problem to be solved by the invention]

[0012] It is an object of the present invention to provide a sustained release injectable composition comprising deslorelin.

[0013] Another object of the present invention is to provide a sustained release injectable composition containing deslorelin comprising uniform microparticles, which can adjust the release rate of deslorelin at the target site, prevent initial over-release, expose an amount sufficient to exhibit the effects of deslorelin, and exhibit the effects of said deslorelin for more than one month.

[0014] Another object of the present invention is to provide a method for producing a sustained release injectable composition containing deslorelin, which can produce microparticles having a uniform particle size and capable of exhibiting a deslorelin release effect for a long period of time. [Means for solving the problem]

[0015] In order to achieve the above object, the present invention provides a sustained release injectable composition containing deslorelin, comprising microparticles, the microparticles comprising deslorelin and a biodegradable polymer, and the value according to the following formula 1 may be 1 to 10: (Formula 1) C max 1d-28d / C max 0-1d Here, a sustained release injectable composition containing deslorelin was administered as an injection to a beagle dog, and the blood concentration of deslorelin was measured. max 1d-28d is the maximum blood concentration of deslorelin within 1 to 28 days after injection, and C max 0-1d This is the maximum blood concentration of deslorelin within one day of administration of the injection.

[0016] The microparticles may have a value of 1 to 2 according to the following formula 2:

number

[0017] The biodegradable polymer may be selected from the group consisting of polylactic acid, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazenes, polyiminocarbonates, polyphosphoesters, polyanhydrides, polyorthoesters, polycaprolactones, polyhydroxyvalers, polyhydroxybutyrates, polyamino acids, and combinations thereof.

[0018] The viscosity of the biodegradable polymer may be 0.1 to 1.0 dl / g.

[0019] The deslorelin and the biodegradable polymer may be contained in a weight ratio of 1:4 to 1:10.

[0020] When administered as an injection, the release rate of deslorelin at the target site is adjusted, and the testosterone suppression effect of deslorelin can be sustained for more than one month.

[0021] The injections are administered and after 10 days testosterone levels are maintained at or below 0.4ng / ml.

[0022] The injectable composition may include a suspending solvent.

[0023] According to another embodiment of the present invention, a method for preparing a sustained release injectable composition containing deslorelin includes the steps of: 1) mixing deslorelin and a biodegradable polymer to prepare a first mixture; 2) dissolving a surfactant in a solvent to prepare a second mixture; 3) injecting the first mixture and the second mixture into a first microchannel and a second microchannel, respectively, having an intersection formed therein, to allow them to flow, thereby generating microparticles at the intersection; 4) collecting the microparticles in a water tank containing the second mixture; 5) removing an organic solvent present in the collected microparticles; 6) washing and drying the microparticles from which the organic solvent has been removed with purified water; and 7) mixing the dried microparticles with a suspension solution, and the value according to the following formula 1 may be 1 to 10: (Formula 1) C max 1d-28d / C max 0-1d Here, a sustained release injectable composition containing deslorelin was administered as an injection to a beagle dog, and the blood concentration of deslorelin was measured. max 1d-28d is the maximum blood concentration of deslorelin within 1 to 28 days after injection, and C max 0-1d is the maximum blood concentration of deslorelin within one day of administration of the injection.

[0024] When the first mixture is injected into the first microchannel, the pressure may be increased under a first condition of 10 to 30 mbar / min after injection under a pressure condition of 700 to 1,500 mbar, and when the injection pressure condition reaches 900 to 1,700 mbar, the pressure may be increased under a second condition of 2 to 8 mbar / min.

[0025] The second mixture is injected into the second microchannel under pressure conditions that are 2 to 4 times higher than the pressure conditions when the first mixture is injected into the first microchannel.

[0026] The step 5) may include the steps of: 5-1) primary stirring at 15-20°C for 20-40 minutes at a speed of 100-300 rpm; 5-2) secondary stirring at 30-40°C for 60-120 minutes at a speed of 100-300 rpm; and 5-3) tertiary stirring at 40-45°C for 4-8 hours at a speed of 100-300 rpm. Effect of the Invention

[0027] The present invention comprises uniform microparticles that can adjust the release rate of deslorelin at a target site, prevent initial over-release, expose an amount of deslorelin sufficient to exhibit the effects of the deslorelin, and exhibit the effects of the deslorelin for more than one month.

[0028] In addition, the microparticles have a uniform particle size, and it is possible to prepare microparticles that can exhibit a long-lasting deslorelin release effect. [Brief description of the drawings]

[0029] [Figure 1] 1 shows the measurement results of pK and PD values ​​of Example 1 according to one embodiment of the present invention. [Diagram 2] 1 shows the measurement results of pK and PD values ​​for Comparative Example 1 according to an embodiment of the present invention. [Diagram 3] 1 shows a comparison result of PD values ​​between Example 1 according to an embodiment of the present invention and Comparative Example 1. [Figure 4] 1 shows the measurement results of pK and PD values ​​of Example 2 according to one embodiment of the present invention. [Diagram 5] 1 shows the measurement results of pK and PD values ​​for Comparative Example 2 according to an embodiment of the present invention. [Figure 6] 11 shows a comparison result of PD values ​​between Example 2 according to an embodiment of the present invention and Comparative Example 2. [Figure 7] 1 is related to the shaking direction for a dissolution experiment according to one embodiment of the present invention. [Figure 8] 1 is a result of an experiment on the dissolution rate of an embodiment according to the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will now be described in detail with reference to exemplary embodiments thereof, in order to enable those skilled in the art to easily practice the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments set forth herein.

[0031] In the present invention, "Deslorelin" may include L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-proline ethylamide and all of its pharma-ceutically acceptable salts.

[0032] In the present invention, "pharmaceutical acceptable" means physiologically tolerable and does not normally cause an allergic reaction or a similar reaction when administered to humans.

[0033] In the present invention, the term "pharmaceutical acceptable salt" refers to an acid addition salt formed with a pharmaceutical acceptable free acid. The free acid may be an organic acid or an inorganic acid. The organic acid may include, but is not limited to, citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, metasulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, glutamic acid, and aspartic acid. The inorganic acid may include, but is not limited to, hydrochloric acid, bromic acid, sulfuric acid, and phosphoric acid.

[0034] The sustained release injectable composition containing deslorelin according to one embodiment of the present invention includes microparticles, the microparticles including deslorelin and a biodegradable polymer, and may have a value of 1 to 10 according to the following formula 1: (Formula 1) C max 1d-28d / C max 0-1d Here, a sustained release injectable composition containing deslorelin was administered as an injection to a beagle dog, and the blood concentration of deslorelin was measured. max 1d-28d is the maximum blood concentration of deslorelin within 1 to 28 days after injection, and C max 0-1d is the maximum blood concentration of deslorelin within one day of administration of the injection.

[0035] The deslorelin is a gonadotropin-releasing hormone agonist (GnRH agonist).

[0036] Gonadotropin-releasing hormone (GnRH) is a naturally occurring hormone produced by the hypothalamus that interacts with receptors in the pituitary gland to stimulate the production of luteinizing hormone (LH).

[0037] To reduce LH production, agonists of the GnRH receptor (GnRH-R), such as leuprolide and goserelin, have been developed. These GnRH agonists are usually of the GnRH decapeptide pyroGlu-His-Trp-SerTyr-Gly-Leu-Arg-Pro-Gly-NH2. For example, GnRH agonists with the D-isomer instead of Gly at position 6 have better biological potency and higher binding affinity / strength to the receptor than the native hormone.

[0038] The GnRH agonist can be used as a chemical castration agent, and is not limited to the above uses, and can be used in any uses that can be utilized based on the effects of the GnRH agonist, without any restrictions.

[0039] As described above, deslorelin is used for chemical castration of animals. In order for the chemical castration effect of deslorelin to occur, the testosterone level must be maintained at 0.4ng / ml or less. That is, deslorelin is a GnGH agonist and can suppress testosterone.

[0040] However, it is known that in order to achieve the above-mentioned effects, when deslorelin is administered into the body by injection or the like, the body must be exposed to an excessive amount of deslorelin immediately after the injection in order for the effects to be achieved.

[0041] Specifically, GnRH agonists such as deslorelin initially act on the pituitary gland to promote the secretion of gonadal hormones, but if administered continuously, the GnRH receptors become deformed, suppressing the secretion of gonadal hormones, and ultimately suppressing the production of testosterone, which finally decreases to the castration level induced by deslorelin (plasma testosterone <0.4ng / ml) after 1 to 3 weeks.

[0042] Due to the above-mentioned characteristics, it has been recognized that in order to rapidly exert the castration effect of deslorelin, an excessive release of the drug at the initial stage of injection is necessary.

[0043] In contrast, the sustained release injectable composition of the present invention can exhibit a chemical castration effect for 1 month, 3 months, 6 months, 12 months, or 24 months, and unlike previously known compositions, can exhibit excellent castration effects while preventing excessive release of deslorelin at the beginning of injection.

[0044] The above formula 1 is based on the results of measuring the blood concentration (pK) of deslorelin in beagle dogs after administration of the sustained release injectable composition containing deslorelin of the present invention.

[0045] The value according to formula 1 may be 1 to 10, 3 to 10, 6 to 10, 7 to 10, 7.5 to 9.5, or 7.5 to 9. Within the above range, initial over-release can be prevented, and the chemical castration effect by deslorelin can be achieved continuously for a desired period of time.

[0046] Specifically, Equation 1 is as follows: (Formula 1) C max 1d-28d / C max 0-1d Here, a sustained release injectable composition containing deslorelin was administered as an injection to a beagle dog, and the blood concentration of deslorelin was measured. max 1d-28d is the maximum blood concentration of deslorelin within 1 to 28 days after injection, and C max 0-1d is the maximum blood concentration of deslorelin within one day of administration of the injection.

[0047] The above Cmax 1d-28d is the maximum blood concentration of deslorelin within 1 to 28 days after administration of the injectable preparation of the present invention, and C max 0-1d is the maximum blood concentration of deslorelin within one day of administration of the injection.

[0048] The value of formula 1 being greater than 1 means that the blood concentration of deslorelin is higher one day after administration of the injectable composition of the present invention to beagle dogs.

[0049] An initial overdose occurs when a drug shows a maximum blood concentration within 24 hours after being administered into the body via injection or other means.

[0050] Since general injectable drugs are administered as a drug itself, the maximum blood concentration is achieved immediately after injection.

[0051] In addition, even in the case of sustained release injectable compositions containing microparticles, the maximum blood concentration can be observed immediately after injection due to differences in the manufacturing process, such as the drug being attached to the surface of the microparticles, the particle size being non-uniform, the particle surface being non-uniform, and differences in the combination of the drug and the biodegradable polymer.

[0052] In contrast, the sustained release injectable composition of the present invention contains microparticles containing deslorelin, but is characterized by not showing a maximum blood concentration within one day after injection and by suppressing initial excessive release.

[0053] Specifically, in the past, deslorelin was overexposed in the early stages to suppress the secretion of gonadal hormones due to deformation of the GnRH receptor, which ultimately suppressed the production of testosterone.

[0054] However, as described below, the results of confirming the testosterone suppression effect using currently available products confirmed that even if there is excessive exposure to deslorelin in the early stages of injection, it does not result in an excellent testosterone suppression effect.

[0055] This means that there is no need to initially release excessive amounts of deslorelin to suppress testosterone, as has been conventionally known.

[0056] The present invention provides a sustained release injectable composition containing microparticles that can suppress initial excessive release and show a maximum blood concentration within 4 weeks, and while suppressing initial excessive release of deslorelin, it allows deslorelin to be released continuously for a desired period of time, thereby showing a sustained testosterone suppression effect.

[0057] When the range value according to the formula 1 is satisfied, it means that the initial excessive release of deslorelin is prevented while a sustained testosterone suppressing effect can be exhibited. When the value according to the formula 1 is greater than 1, it means that the maximum blood concentration of deslorelin within 1 to 28 days is greater than the maximum blood concentration of deslorelin within 1 day.

[0058] As explained above, experimental results show that excessive release of deslorelin at the beginning of injection is not necessary to effectively suppress testosterone. Also, in order to show a long-lasting testosterone suppression effect, a certain level of testosterone must be exposed for 1 to 28 days after injection. This is because the testosterone suppression effect appears due to the transformation of GnRH receptors, and a certain period of sustained release of deslorelin is necessary to transform and maintain the GnRH receptors.

[0059] The sustained release injectable composition of the present invention has an AUC of 500day*pg / ml to 1,500day*pg / ml, 700day*pg / ml to 1,300day*pg / ml, or even 750day*pg / ml to 1,100day*pg / ml, as measured within one week after injection into beagle dogs. This more clearly confirms that there is no initial over-release, at a level of about 12.9% compared to conventional products.

[0060] Therefore, the present invention is characterized in that the value according to formula 1 is 1 to 10, and within the above range, the testosterone suppression effect can be exhibited for 1 month, 3 months, 6 months, 12 months, or 24 months.

[0061] The microparticles may have a value of 1 to 2 according to the following formula 2:

number

[0062] The D10, D50 and D90 refer to measurements of the diameter of a microparticle, and refer to values ​​corresponding to 10%, 50% and 90% of the maximum value on the cumulative distribution.

[0063] The above formula 2 defines the ratio of (D90-D50) and (D50-D10), and confirms the degree of uniform particle distribution by checking the ratio of the difference between the diameter of a particle corresponding to 90% and the diameter of a particle corresponding to 50%, and the difference between the diameter of a particle corresponding to 50% and the diameter of a particle corresponding to 10%, relative to the maximum value in the cumulative distribution of particles within the average particle distribution, and the closer the value is to 1, the more uniform the distribution width is.

[0064] Formula 2 of the present invention is for more clearly confirming the size distribution of microparticles, and the value according to formula 2 may be 1-2, 1.1-1.9, 1.2-1.8, or 1.3-1.7. When the value according to formula 2 is satisfied and the average diameter of the microparticles is 65-100 μm, it means that the size of the microparticles is distributed close to the average diameter value. This means that when microparticles of uniform size are injected into the body by injection, the microparticles having uniform sizes are biodegraded to a similar extent, and the biodegradation of the microparticles can show the release effect of deslorelin.

[0065] That is, the release degree of deslorelin in the body of microparticles containing deslorelin is highly related to the particle size and specific surface area, and in order to increase the specific surface area, it is essential to use microparticles with uniform diameter.As described above, by using microparticles with very uniform particle size, it is possible to prevent initial over-release when injected into the body, and to show the release effect of deslorelin for a long time, and the castration effect of deslorelin can be exerted for more than one month.

[0066] The weight ratio of the deslorelin and the biodegradable polymer may be 1:4 to 1:10, 1:5 to 1:8, 1:6 to 1:7, or 1:6.6667. When mixed within the above range, deslorelin can be released continuously for a long period of time due to the degradation of the biodegradable polymer.

[0067] The biodegradable polymer is selected from the group consisting of polylactic acid, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazene, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, polyamino acid, and combinations thereof, preferably polylactide-co-glycolide (PLGA) or polylactide (PLA), but not limited to the above examples.

[0068] The viscosity of the biodegradable polymer may be 0.1 to 1.0 dl / g. As described above, the sustained release of deslorelin is affected by the average diameter, size distribution, and surface condition of the microparticles, but in addition to the above factors, the combination of the biodegradable polymer and the drug can also show a large difference.

[0069] The biodegradable polymer is a product that can be injected into the body, and may have a viscosity range of 0.1-1.0 dl / g, 0.1-0.9 dl / g, 0.15-0.8 dl / g, 0.15-0.7 dl / g, or 0.2-0.65 dl / g. When used within the above range, initial over-release is suppressed by combination with deslorelin, but an appropriate level of deslorelin release occurs even at the beginning of injection, and deslorelin release effect can be sustained for 1 month, 3 months, 6 months, 12 months, or 24 months.

[0070] Furthermore, the microparticles of the present invention can be produced using one type of biodegradable polymer, or two or more types of biodegradable polymers.

[0071] Specifically, the microparticles contained in the sustained release injectable composition of the present invention may contain only one type of biodegradable polymer, or may contain two or more types of biodegradable polymers. A large number of the microparticles may be contained in the sustained release injectable composition, and each of the microparticles may contain a different biodegradable polymer.

[0072] That is, microparticles containing one type of biodegradable polymer may be included in the injectable composition, and microparticles containing different biodegradable polymers may be included in the injectable composition.

[0073] The biodegradable polymer may include a polymer exhibiting a viscosity range of 0.1 to 0.3 dl / g or 0.3 to 0.7 dl / g.

[0074] Specifically, the sustained release injectable composition may contain microparticles selected from the group consisting of microparticles containing a biodegradable polymer having a viscosity of 0.1 to 0.3 dl / g, microparticles containing a biodegradable polymer having a viscosity of 0.3 to 0.7 dl / g, and a mixture thereof.

[0075] The biodegradable polymer having a viscosity of 0.1 to 0.3 dl / g may be specifically 0.13 to 0.28 dl / g, 0.15 to 0.25 dl / g, or 0.22 dl / g. By including a biodegradable polymer having a viscosity in the above range, it is possible to prevent initial excessive release of deslorelin, and to exhibit a sustained release effect of deslorelin for 1 month, 3 months, 6 months, 12 months, or 24 months.

[0076] The biodegradable polymer having a viscosity of 0.3 to 0.7 dl / g is specifically 0.45 to 0.65 dl / g, 0.5 to 0.6 dl / g, or may be 0.57 dl / g. By including a biodegradable polymer having a viscosity in the above range, it is possible to prevent initial excessive release of deslorelin, and to exhibit a sustained release effect of deslorelin for 1 month, 3 months, 6 months, 12 months, or 24 months.

[0077] In addition, microparticles containing the low-viscosity biodegradable polymer degrade relatively quickly in the body, resulting in the end of the release of deslorelin, while microparticles containing the high-viscosity biodegradable polymer degrade relatively slowly in the body, and the initial release of deslorelin may not occur.

[0078] Therefore, by manufacturing microparticles containing two or more biodegradable polymers with different viscosities and containing all of these, it is possible to demonstrate an initial release of deslorelin and a long-lasting deslorelin release effect.

[0079] As described below, the injectable composition can contain microparticles containing different biodegradable polymers by the manufacturing method of the present invention. That is, the conventional method for manufacturing microparticles containing biodegradable polymers does not allow the size of the particles to be controlled, so it is impossible to manufacture particles of uniform size, and it is impossible to manufacture microparticles using different biodegradable polymers and mix them to provide a sustained release injectable composition.

[0080] However, as described below, the present invention uses a manufacturing method that allows the particle size to be controlled and the particles produced to be very uniform in size and have a uniform surface shape, and two or more types of biodegradable polymers are used to produce microparticles each containing deslorelin, which can then be mixed together to provide a sustained release injectable composition.

[0081] A method for producing a sustained release injectable composition containing deslorelin according to another embodiment of the present invention includes the steps of: 1) mixing deslorelin and a biodegradable polymer to produce a first mixture; 2) dissolving a surfactant in a solvent to produce a second mixture; 3) injecting the first and second mixtures into a first and second microchannels, respectively, having an intersection formed therein, to allow them to flow, thereby generating microparticles at the intersection; 4) collecting the microparticles in a water tank containing the second mixture; 5) removing the organic solvent present in the collected microparticles; 6) washing and drying the microparticles from which the organic solvent has been removed with purified water; and 7) mixing the dried microparticles with a suspension solution.

[0082] Step 1) is a step of preparing a first mixture, in which deslorelin and a biodegradable polymer are dissolved in an organic solvent to prepare the first mixture, and the biodegradable polymer is selected from the group consisting of polylactic acid, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazene, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, polyamino acid, and combinations thereof, preferably polylactide-co-glycolide (PLGA) or polylactide (PLA), but is not limited to the above examples.

[0083] In addition, the organic solvent is one that is not miscible with water, and is, for example, any one or more selected from the group consisting of chloroform, chloroethane, dichloroethane, trichloroethane, and mixtures thereof, and is preferably dichloromethane, but is not limited to these examples. It can be said that any organic solvent that can dissolve the biodegradable polymer and deslorelin and can be easily selected by a person skilled in the art, and is not limited to the above examples, can be used.

[0084] In step 1), a first mixture is prepared by dissolving deslorelin and a biodegradable polymer, and the solvent is an organic solvent as described above. This is because the deslorelin and the biodegradable polymer are completely dissolved using the organic solvent by utilizing the solubility properties of the deslorelin and the biodegradable polymer.

[0085] More specifically, deslorelin acetate was dissolved in a first solvent, and a biodegradable polymer was dissolved in a second solvent. Then, the deslorelin acetate mixture dissolved in the first solvent and the biodegradable polymer mixture dissolved in the second solvent were mixed to prepare a first mixture.

[0086] The weight ratio of deslorelin and the biodegradable polymer in the first mixture may be 1:4 to 1:10, 1:5 to 1:8, 1:6 to 1:7, or 1:6.6667. When used in a mixture within the above range, deslorelin can be released continuously for a long period of time due to the degradation of the biodegradable polymer.

[0087] If the weight ratio of the deslorelin and the biodegradable polymer is less than 1:4, i.e., if the biodegradable polymer is contained in a ratio less than this, the weight ratio of the biodegradable polymer will be low compared to the weight of deslorelin, and it may be difficult to produce sustained release particles in which deslorelin is uniformly distributed in spherical biodegradable polymer particles. If the weight ratio of the biodegradable polymer and the deslorelin exceeds 1:10, i.e., if the biodegradable polymer is contained in an amount greater than this weight ratio, the content of deslorelin in the sustained release particles will be low, and a problem may arise in which a large amount of sustained release particles must be administered to administer the desired concentration of drug.

[0088] More specifically, the biodegradable polymer in the first mixture is contained in an amount of 15 to 25% by weight, and preferably 20% by weight, but is not limited to this example.

[0089] The step 2) is a step of preparing a second mixture, and the second mixture is prepared by dissolving a surfactant in water. The surfactant can be used without limitation as long as it can assist the biodegradable polymer solution in forming a stable emulsion. Specifically, the surfactant is any one or more selected from the group consisting of nonionic surfactants, anionic surfactants, cationic surfactants, and mixtures thereof, and more specifically, any one or more selected from the group consisting of methylcellulose, polyvinylpyrrolidone, lecithin, gelatin, polyvinyl alcohol, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, sodium lauryl sulfate, sodium stearate, esteramines, linear diamines, fatiamines, and mixtures thereof, and preferably polyvinyl alcohol, but is not limited to the above.

[0090] The second mixture contains 0.1 to 1.0 wt %, 0.3 to 0.7 wt %, or 0.5 wt % of the surfactant, and the remainder is all water.

[0091] The step 3) is a step of injecting the first mixture and the second mixture into a microchannel formed on the wafer so that they flow.

[0092] More specifically, the microchannel is formed from a material selected from the group consisting of a silicon wafer or a polymer film, but the examples of the material are not limited to the above examples, and any material capable of forming a microchannel can be used.

[0093] The polymer film may be selected from the group consisting of, but is not limited to, polyimide, polyethylene, fluorinated ethylene propylene, polypropylene, polyethylene terephthalate, polyethylene naphthalate, polysulfone, and mixtures thereof.

[0094] For example, aluminum is deposited on a silicon wafer using an e-beam evaporator, and photoresist is patterned on the aluminum using photolithography. The photoresist is then used as a mask to etch the aluminum, and after removing the photoresist, silicon is etched by DRIE (deep ion reactive etching) using the aluminum as a mask. After removing the aluminum, glass is anodically bonded onto the wafer to seal it, and the microchannel is manufactured.

[0095] The microchannel has an average diameter of 80 to 120 μm, preferably 100 μm, but is not limited to this example. If the average diameter of the microchannel is 80 μm or less, the diameter of the sustained release particles produced may be as small as less than 40 μm, which may affect effective drug release and in vivo absorption. In addition, if the average size of the sustained release particles produced exceeds 100 μm, foreign body sensation and pain increase when administered as an injection, and the particle size distribution of the produced particles becomes large, making it difficult to produce sustained release particles with a uniform particle size.

[0096] However, the average diameter of the microchannels can vary depending on the range of injection pressures, and is closely related to the average diameter of the particles, but also to the injection pressures of the first and second mixtures.

[0097] In addition, the cross-sectional width (w) and cross-sectional height (d) of the microchannel are closely related to the average diameter (d') of the controlled release particles produced. The cross-sectional width (w) of the microchannel is in a ratio range of 0.7 to 1.3 to the average diameter (d') of the controlled release particles, and the cross-sectional height (d) of the microchannel is in a ratio range of 0.7 to 1.3 to the average diameter (d') of the controlled release particles.

[0098] In other words, once the average diameter (d') of the controlled release particles to be produced is determined, the cross-sectional width (w) and height (d) of the microchannel can be set within a ratio range of 0.7 to 1.3 of d', making it possible to produce controlled release particles of the desired size.

[0099] The step 3) is to allow the first mixture and the second mixture to flow through the first microchannel and the second microchannel where an intersection is formed under the injection pressure condition.

[0100] That is, a first mixture flows along a first microchannel and a second mixture flows along a second microchannel shaped to form an intersection with the first microchannel to meet the flow of the first mixture.

[0101] More specifically, when the first mixture is injected into the first microchannel, the pressure may be increased under a first condition of 10 to 30 mbar / min after the injection pressure condition reaches 900 to 1,700 mbar, and the pressure may be increased under a second condition of 2 to 8 mbar / min.

[0102] Also, the second mixture may be injected into the second microchannel under pressure conditions that are 2 to 4 times higher than the pressure conditions when the first mixture is injected into the first microchannel.

[0103] Specifically, in the manufacturing method using the microchannel, when the flow rates of the first mixture and the second mixture flowing inside the microchannel were set to constant values ​​using a flow meter and the pressure was measured by feedback control, it was confirmed that the pressure required to make the first mixture flow through the microchannel at a constant flow rate gradually increased over time.

[0104] Therefore, by using a method in which the pressure applied to the first mixture is steadily increased to minimize variability in the flow rate and the first mixture gradually hardens inside the microchannel, problems of non-uniform microparticle distribution or channel blockage can be prevented and the production yield of the targeted microparticles can be increased.

[0105] In addition, the pressure conditions when injecting the first mixture and the second mixture into the microchannel are for controlling the average diameter of the produced microparticles, and if the above range is not specifically satisfied, problems may occur in which the size of the produced particles is not uniform, the average diameter range of the microparticles of the present invention is not satisfied, or the value of Equation 1 is not satisfied.

[0106] That is, the second mixture is made to flow under higher pressure conditions so that the flow of the second mixture that forms an intersection with the flow of the first mixture flows at a faster flow rate than the flow of the first mixture injected into the linear microchannel.

[0107] As described above, by making the flow rates of the first mixture and the second mixture different and making the flow rate of the second mixture faster than that of the first mixture, the second mixture, which has a relatively faster flow rate, compresses the first mixture at the point where the flows of the first and second mixtures meet, and at this time, the biodegradable polymer and deslorelin in the first mixture form spherical microparticles due to the repulsive force between the first and second mixtures, more specifically, microparticles in which deslorelin is uniformly distributed on the spherical biodegradable polymer are formed.

[0108] The step 4) is a step of collecting the microparticles, and the microparticles are collected in a water bath containing the second mixture to prevent aggregation between the initially generated microparticles.

[0109] Step 4) is used to prevent aggregation between collected microparticles by using the second mixture prepared in step 2), i.e., a mixed solution of surfactant and water, to prepare the second mixture in step 2), injecting a portion of the mixture into a microchannel and transferring the other portion to a water tank in step 4).

[0110] The step 5) is a step for removing the organic solvent present on the microparticles collected in the water tank, and the organic solvent present on the surface of the controlled release particles is evaporated and removed by stirring under a certain temperature condition and stirring speed. At this time, the stirring conditions include 5-1) a first stirring step at a speed of 100-300 rpm for 20-40 minutes at 15-20°C, 5-2) a second stirring step at a speed of 100-300 rpm for 60-120 minutes at 30-40°C, and 5-3) a third stirring step at a speed of 100-300 rpm for 4-8 hours at 40-45°C.

[0111] The stirring speed is set to different temperature conditions and stirring progress times in the first and second stirring steps to proceed with the stirring process.

[0112] As described above, the temperature condition is increased in the second stirring step compared to the first stirring step, and the temperature is increased stepwise to control the evaporation rate of the organic solvent present on the surface of the microparticles, i.e., the organic solvent present on the surface of the microparticles is gradually evaporated to produce the microparticles.

[0113] The temperature of the first and second mixtures when they flow through the microchannels is also 15 to 20°C, and preferably 17°C. That is, after they flow through the microchannels and form an intersection to generate microparticles, the low temperature is maintained at a constant 15 to 20°C until the collected microparticles are subjected to the first stirring. Only by maintaining a low temperature during the microparticle production process can spherical particles be produced and maintained. That is, if the low temperature conditions are not met, problems arise in which it is difficult to produce uniform spherical particles.

[0114] Thereafter, in the second and third stirring processes, the temperature is gradually increased and the stirring time is increased so that the organic solvent present on the surface of the microparticles is gradually evaporated, and the effect on the surface of the microparticles due to the evaporation of the organic solvent from the surface can be minimized. That is, if the organic solvent is evaporated suddenly, the surface of the microparticles may become rough and not smooth due to the evaporation of the organic solvent. In order to prevent this problem, the temperature condition is gradually increased as described above, and the time for proceeding with the stirring process is also increased, so that the evaporation rate of the organic solvent can be controlled, and the surface roughness of the manufactured microparticles can be controlled by controlling the evaporation rate of the organic solvent.

[0115] Finally, step 6) is a step of washing and drying the microparticles. After stirring to remove all organic solvent from the surface of the microparticles, the microparticles are washed several times with sterilized and filtered purified water to remove any surfactant remaining on the microparticles, and then freeze-dried.

[0116] The final microparticles are spherical microparticles made of biodegradable polymers in which deslorelin is uniformly distributed, and contain deslorelin and biodegradable polymer in a weight ratio of 1:4 to 1:10.

[0117] The weight ratio of deslorelin and the biodegradable polymer contained in the microparticles is the same as the weight ratio in the first mixture, which is because microparticles are produced and then all of the organic solvent is evaporated to remove, thereby producing microparticles containing deslorelin and the biodegradable polymer in the same weight ratio as in the first mixture.

[0118] The prepared microparticles can be mixed with a suspension solvent to prepare an injectable composition.

[0119] The suspension medium comprises an isotonicity agent, a suspending agent and a solvent.

[0120] More specifically, the tonicity agent may be selected from the group consisting of D-Mannitol, Maltitol, Sorbitol, Lactitol, Xylitol, Sodium chloride, and mixtures thereof, preferably D-Mannitol, but is not limited to the above examples.

[0121] The suspending agent may be sodium carboxymethylcellulose, polysorbate 80, starch, starch derivatives, polyhydric alcohols, chitosan, chitosan derivatives, cellulose, cellulose derivatives, collagen, gelatin, hyaluronic acid (HA), alginic acid, algin, pectin, carrageenan, chondroitin, chondroitin sulfate, dextran, dextran sulfate, polylysine, titin, fibrin, agarose, fluran, xanthan gum, etc. gum), and mixtures thereof, preferably sodium carboxymethylcellulose and polysorbate 80, but not limited to the above examples.

[0122] The solvent may be water for injection, and any solvent that can be used as water for injection may be used without limitation.

[0123] Manufacturing Example 1 Preparation of microparticles containing deslorelin Deslorelin acetate was dissolved in methanol to prepare an API mixture. PLGA and PLA with a viscosity of 0.22 dl / g were dissolved in dichloromethane to prepare a biodegradable polymer mixture. The weight ratio of PLGA and PLA in the biodegradable polymer mixture was 1.7:18.3.

[0124] The API mixture and the biodegradable polymer mixture were mixed to prepare a first mixture, in which the weight ratio of deslorelin acetate to the biodegradable polymer in the first mixture was 1:6.6667.

[0125] A surfactant, polyvinyl alcohol, was mixed with water to produce a second mixture containing 0.5% by weight of polyvinyl alcohol.

[0126] The first and second mixtures were injected and allowed to flow through a microchannel formed on a silicon wafer.

[0127] In order to make the first and second mixtures flow at a constant flow rate, the first mixture was flowed under conditions where the pressure was increased at a constant rate of 20 mbar per minute starting at 1000 mbar, and then changed to a rate of 7 mbar per minute when it reached 1200 mbar, while the second mixture was flowed under a pressure condition of 3000 mbar. The temperature condition was 17° C. and the stirring speed was maintained at 300 rpm.

[0128] The microparticles generated at the intersection where the first mixture flow and the second mixture flow meet were collected in a water tank containing the second mixture. The microparticles collected in the water tank were first stirred at 300 rpm for 30 minutes at 17°C, then the temperature was increased to 38°C and the second stirring was performed at 400 rpm for 1 hour, and then the temperature was increased to 45°C and the third stirring was performed at 500 rpm for 3 hours.

[0129] After the stirring was completed, the microparticles were washed several times with sterilized and filtered purified water and freeze-dried to produce microparticles.

[0130] Manufacturing Example 2 A biodegradable polymer mixture was prepared by dissolving PLA having a viscosity of 0.37 dl / g in methanol, and microparticles were prepared from the mixture in the same manner as in Preparation Example 1.

[0131] Production Example 3 Microparticles were produced in the same manner as in Production Example 1, except that PLA having a viscosity of 0.57 dl / g as the biodegradable polymer was dissolved in methanol to produce a biodegradable polymer mixture.

[0132] Production Example 4 PLGA having a viscosity of 0.22 dl / g and PLA having a viscosity of 0.41 dl / g were dissolved in methanol to prepare a biodegradable polymer mixture, and microparticles were prepared in the same manner as in Preparation Example 1, except that the weight ratio of PLGA to PLA in the biodegradable polymer mixture was 1.7:18.3.

[0133] Example 1 The microparticles of Preparation Example 1 were added to 2.0 ml of a suspension solvent per vial and then uniformly suspended to prepare a subcutaneous injection composition. The weight ratio of deslorelin acetate and biodegradable polymer in the subcutaneous injection composition was 1:6.6667.

[0134] The suspension solvent had the composition shown in Table 2 below.

[0135] [Table 1]

[0136] Example 2 A composition for subcutaneous injection was prepared in the same manner as in Example 1, except that the microparticles of Preparation Example 1 and the microparticles of Preparation Example 2 were mixed in a weight ratio of 1:0.92.

[0137] Example 3 A composition for subcutaneous injection was prepared in the same manner as in Example 1, except that the microparticles of Preparation Example 1 and the microparticles of Preparation Example 3 were mixed in a weight ratio of 1:0.92.

[0138] Example 4 A composition for subcutaneous injection was prepared in the same manner as in Example 1, except that the microparticles of Preparation Example 4 were mixed in place of the microparticles of Preparation Example 1.

[0139] Comparative Example 1 As a comparative example, commercially available Suprelorin 4.7 mg Implant (containing 4.7 mg of deslorelin) was used.

[0140] Comparative Example 2 As a comparative example, commercially available Suprelorin 9.4 mg Implant (containing 9.4 mg of deslorelin) was used.

[0141] Experimental Example 1 Examination of the properties of microparticles To specifically ascertain the diameter of the microparticles, analysis was carried out using a Microtrac particle size analyzer.

[0142] [Table 2]

[0143] As shown in Table 2, the particle size analysis of the Preparation Examples confirmed that the average diameters (D50) were 80.09 μm, 95.45 μm, 68.62 μm, and 83.38 μm. The values ​​calculated by the formula were all 1.11, 1.06, 1.30, and 1.67, all within the range of 1 to 2, confirming that the particles had very uniform diameters from D10 to D95.

[0144] Experimental Example 2 Pharmacokinetic characterization 1 The pharmacokinetic evaluation of Example 1 and Comparative Example 1 of the present invention was confirmed.

[0145] For the evaluation, Example 1 and Comparative Example 1 were administered to beagle dogs, blood was collected, and the blood concentration of deslorelin (PK) and the blood concentration of testosterone (PD) were measured.

[0146] The injection containing the microparticles of Preparation Example 1 used as the 6-month or longer sustained release dosage form contained 6.11 mg of deslorelin.

[0147] For the experiment, Example 1 and Comparative Example 1 were administered to five beagle dogs each, via subcutaneous injection.

[0148] After blood sampling, the average values ​​of PK and PD for the five beagle dogs were calculated. The experimental results are shown in Tables 3 and 4 and Figures 1 to 3 below.

[0149] [Table 3]

[0150] Table 3 shows the pK and PD values ​​for Example 1, which is a sustained release injectable composition capable of continuously releasing deslorelin for 6 months. To derive the values ​​according to formula 1, the maximum blood concentration of deslorelin from 1 day to 28 days is 605 pg / ml, and the maximum blood concentration of deslorelin within 1 day is 68 pg / ml. The value of the formula is 8.9, which can be confirmed to be within the scope of the present invention.

[0151] It was also confirmed that when the PD value is below 0.4 ng / ml, the testosterone suppression effect appears after two weeks.

[0152] [Table 4]

[0153] Table 4 shows the pK and PD values ​​for Comparative Example 1, which shows that deslorelin can be continuously released for 6 months. To derive the value according to the formula 1, the maximum blood concentration of deslorelin from 1 day to 28 days is 697 pg / ml, and the maximum blood concentration of deslorelin within 1 day is 17,624 pg / ml. It can be confirmed that the value of the formula is 0.04, which is not within the scope of the present invention.

[0154] In addition, it was confirmed that when the PD value was 0.4 ng / ml or less, the testosterone suppression effect appeared after 2 weeks. However, after 26 weeks, the testosterone value increased again, and it was confirmed that, compared to Example 1, no sustained testosterone suppression effect appeared.

[0155] The results of the pharmacokinetic property analysis for Example 1 and Comparative Example 1 are summarized as follows.

[0156] [Table 5]

[0157] According to the results of the experiment, the maximum blood concentration of deslorelin was confirmed two weeks after injection in the case of Example 1, and one hour after injection in the case of Comparative Example 1. In other words, it can be confirmed that the initial excessive release of deslorelin occurs in Comparative Example 1, whereas the initial excessive release is suppressed in the case of Example 1.

[0158] In addition, the total AUC was confirmed to be at the same level, but the AUC within one week was confirmed to be at about 12.9% level in Example 1 compared to Comparative Example 1, confirming a large difference in the amount of deslorelin exposed within one week after injection.

[0159] Experimental Example 3 Pharmacokinetic characterization 2 The pharmacokinetic evaluation of Example 2 of the present invention and Comparative Example 2 was confirmed.

[0160] For the evaluation, Example 2 and Comparative Example 2 were administered to beagle dogs, blood was collected, and the blood concentration of deslorelin (PK) and the blood concentration of testosterone (PD) were measured.

[0161] The injections containing the microparticles of Preparations 1 and 2 used as the 12-month or longer sustained release dosage form contained 11.75 mg of deslorelin.

[0162] For the experiment, Example 2 and Comparative Example 2 were administered to five beagle dogs each, and the administration route was subcutaneous injection.

[0163] After blood sampling, the average values ​​of PK and PD for the five beagle dogs were calculated. The experimental results are shown in Tables 6 and 7 and Figures 4 to 6 below.

[0164] [Table 6]

[0165] Table 6 shows the pK and PD values ​​for Example 2, which is a sustained release injectable composition capable of continuously releasing deslorelin for 12 months. To derive the values ​​according to formula 1, the maximum blood concentration of deslorelin from 1 day to 28 days is 1,213 pg / ml, and the maximum blood concentration of deslorelin within 1 day is 146 pg / ml. The value of the formula is 8.31, which can be confirmed to be within the scope of the present invention.

[0166] It was also confirmed that when the PD value is below 0.4 ng / ml, the testosterone suppression effect appears after one week.

[0167] [Table 7]

[0168] Table 7 shows the pK and PD values ​​for Comparative Example 2, which shows that deslorelin can be sustainedly released for 12 months. To derive the values ​​according to the formula 1, the maximum blood concentration of deslorelin from 1 day to 28 days is 1,922 pg / ml, and the maximum blood concentration of deslorelin within 1 day is 51,975 pg / ml. It can be confirmed that the value of the formula is 0.04, which is not within the scope of the present invention.

[0169] It was also confirmed that when the PD value is below 0.4 ng / ml, the testosterone suppression effect appears after one week.

[0170] Comparing Example 2 and Comparative Example 2, it can be seen that the same testosterone suppression effect is observed for more than 28 weeks. However, Example 2 of the present invention is different from Comparative Example 2, which is an existing product, in that it has a long-lasting testosterone suppression effect by controlling the release of deslorelin without initial over-release.

[0171] The results of the pharmacokinetic property analysis for Example 2 and Comparative Example 2 are summarized as follows.

[0172] [Table 8]

[0173] According to the results of the experiment, the maximum blood concentration of deslorelin was confirmed 3 weeks after injection in the case of Example 2, and 1 hour after injection in the case of Comparative Example 2. In other words, it can be confirmed that the initial excessive release of deslorelin occurs in Comparative Example 2, whereas the initial excessive release is suppressed in the case of Example 2.

[0174] In addition, the total AUC in Example 2 was confirmed to be approximately 56% of that in Comparative Example 2, and the AUC within one week in Example 2 was confirmed to be approximately 12.9% of that in Comparative Example 2, demonstrating a significant difference in the amount of deslorelin exposed after injection.

[0175] Experimental Example 4 Drug elution experiments Drug elution experiments were carried out for Examples 1 to 4 and Comparative Examples 1 and 2.

[0176] The dissolution test solution was prepared by mixing 4 g of PVA and 1 g of Tween 80 in 1,000 ml of water.

[0177] A shaking water bath was used as the dissolution tester, and a glass test vessel with a capacity of 120 ml was used as the dissolution test vessel. The operating conditions were as shown in Figure 7, with the vessel being shaken horizontally in the vertical direction to the bottom of the vessel, at 55°C and 150 times (reciprocating).

[0178] The experimental results are shown in FIG. 8 and Table 9.

[0179] [Table 9]

[0180] Example 1 and Comparative Example 1 are all 6-month dosage forms, while Example 2 and Comparative Example 2 are 12-month dosage forms. Comparing the dissolution rates, it was confirmed that the Examples release deslorelin for a longer period of time than the Comparative Examples.

[0181] Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements made by those skilled in the art using the basic concept of the present invention defined in the following claims also fall within the scope of the present invention.

Claims

1. Contains microparticles, The microparticles comprise deslorelin and a biodegradable polymer; The biodegradable polymer is selected from the group consisting of polylactide (PLA) and polylactide-co-glycolide (PLGA) and combinations thereof; A sustained release injectable composition comprising deslorelin, wherein the value according to the following formula 1 is 1 to 10 and the value according to the following formula 2 is 1 to 2: (Formula 1) C max 1d-28d / C max 0-1d [0010] In formula 1, the C max 1d-28d and the above C max 0-1d is a value obtained by administering the sustained release injectable composition containing deslorelin as an injection to a beagle dog and measuring the blood concentration of deslorelin, Said C max 1d-28d is the maximum blood concentration of deslorelin within 1 to 28 days after administration of the injection, Said C max 0-1d is the maximum blood concentration of deslorelin within one day of administration of the injection, In formula 2, D10 is a particle diameter corresponding to 10% Tile with respect to the maximum value in the cumulative distribution of the particle diameters, The D50 is a particle diameter corresponding to a 50% Tile with respect to the maximum value in the cumulative distribution of the particle diameters, The D90 is the diameter of a particle that corresponds to the 90% tile with respect to the maximum value in the cumulative distribution of the particle diameters.

2. The sustained release injectable composition containing deslorelin according to claim 1, wherein the viscosity of the biodegradable polymer is 0.1 to 1.0 dl / g.

3. The sustained release injectable composition containing deslorelin according to claim 1, wherein the deslorelin and the biodegradable polymer are contained in a weight ratio of 1:4 to 1:

10.

4. The sustained release injectable composition comprising deslorelin according to claim 1, wherein when administered as an injection, the release rate of deslorelin at the target site is adjusted, and the testosterone suppression effect of deslorelin lasts for one month or more.

5. The sustained release injectable composition comprising deslorelin according to claim 1, wherein testosterone is maintained at 0.4 ng / ml or less 10 days after administration of the injection.

6. The sustained release injectable composition comprising deslorelin according to claim 1, wherein the injectable composition comprises a suspension solvent.

7. 1) mixing deslorelin and a biodegradable polymer to produce a first mixture; 2) dissolving a surfactant in a solvent to produce a second mixture; 3) injecting and flowing the first mixture and the second mixture into a first microchannel and a second microchannel, respectively, at an intersection to generate microparticles at the intersection; 4) collecting the microparticles in a water bath containing the second mixture; 5) removing the organic solvent present on the collected microparticles; 6) washing the microparticles from which the organic solvent has been removed with purified water and drying; 7) mixing the dried microparticles with a suspension solvent; The biodegradable polymer is selected from the group consisting of polylactide (PLA) and polylactide-co-glycolide (PLGA) and combinations thereof; When the first mixture is injected into the first microchannel, the pressure is increased under a first condition of 10 to 30 mbar / min after the first mixture is injected under a pressure condition of 700 to 1,500 mbar. When the injection pressure condition reaches 900 to 1,700 mbar, the pressure is increased under a second condition of 2 to 8 mbar / min; A method for preparing a sustained release injectable composition containing deslorelin, the composition being such that the value according to the following formula 1 is 1 to 10 and the value according to the following formula 2 is 1 to 2: (Formula 1) C max 1d-28d / C max 0-1d [0025] In formula 1, the C max 1d-28d and the above C max 0-1d is a value obtained by administering the sustained release injectable composition containing deslorelin as an injection to a beagle dog and measuring the blood concentration of deslorelin, Said C max 1d-28d is the maximum blood concentration of deslorelin within 1 to 28 days after administration of the injection, Said C max 0-1d is the maximum blood concentration of deslorelin within one day of administration of the injection, In Equation 2, D10 is the diameter of a particle corresponding to 10% of the maximum value in the cumulative distribution of the particles, The D50 is a diameter of a particle corresponding to 50% of the maximum value in a cumulative distribution of the particles, The D90 is the diameter of the particles that corresponds to 90% of the maximum value in the cumulative distribution of the particles.

8. The first mixture is injected into the first microchannel under a pressure condition of 700 to 1,500 mbar, and then the pressure is increased under a first condition of 10 to 30 mbar / min; The method for preparing a sustained release injectable composition comprising deslorelin according to claim 7, wherein when the injection pressure condition reaches 900-1,700 mbar, the pressure is increased under a second condition of 2-8 mbar / min.

9. The method for producing a sustained release injectable composition containing deslorelin according to claim 7, wherein the second mixture is injected into the second microchannel under pressure conditions that are 2 to 4 times higher than the pressure conditions when the first mixture is injected into the first microchannel.

10. The step 5) comprises: 5-1) performing primary stirring at a speed of 100 to 300 rpm at 15 to 20° C. for 20 to 40 minutes; 5-2) secondary stirring at 30-40° C. for 60-120 minutes at a speed of 100-300 rpm; 5-3) a third stirring step at a speed of 100 to 300 rpm at 40 to 45° C. for 4 to 8 hours.

Citation Information

Patent Citations

  • Chemical method for sexual sterilisation and libido suppression in male mammals

    KR1020120052355A

  • Sustained-release injection comprising deslorelin, and preparation method therefor

    WO2020130585A1

  • Sustained-release microparticles containing deslorelin, and preparation method therefor

    WO2020222399A1